We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Himax (HIMX) to Report Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
Himax Technologies (HIMX - Free Report) is set to report first-quarter 2021 results on May 6.
The Zacks Consensus Estimate for revenues is currently pegged at $302.8 million, indicating growth of 64% from the year-ago quarter’s reported figure.
Moreover, the consensus mark for earnings has been stable at 38 cents per share in the past seven days. Meanwhile, Himax reported earnings of 2 cents per share in the year-ago quarter.
Let’s see how things are shaping up for this announcement.
Himax delivered impressive preliminary first-quarter 2021 results. Revenues of $309 million increased 12.1% sequentially and 67.4% year over year. The company’s earlier guidance suggested an increase between 5% and 10%, sequentially.
Earnings per ADS on non-IFRS basis are expected to be 38.4 cents, exceeding the prior guidance of 30.1-34.1 cents per ADS.
Further, the company’s gross margin exceeded its guidance, reflecting stringent cost-control efforts.
Factors to Consider
Himax is likely to have gained from a rebounding smartphone market, which is expected to have led to an uptick in demand for its smartphone TDDI solutions, AMOLED driver ICs and PMIC for 5G smartphones.
Continued momentum in demand for automotive driver ICs, owing to recovery in the automotive sector along with increasing usage of WLO in technologies across nanoimprinting manufacturing and diffraction optics might have acted as tailwinds.
Solid demand for high-end monitor and new-generation low-power notebooks and tablets owing to the coronavirus-led continuation in work-from-home and online-learning set up is expected to have triggered the need for Himax’s display driver ICs and timing controllers, which in turn, might have impacted first-quarter top line.
Momentum for its CMOS image sensors across IP camera and notebook is expected to have contributed to first-quarter revenues.
However, weakness in TDIC sales as well as traditional smartphone DDICs is likely to have acted as headwinds. Also, the company had earlier noted (Feb 4, 2021) that it expects AMOLED IC sales to witness sequential decline in the first quarter due to capacity shortage.
What Our Model Says
Our proven model doesn’t conclusively predict an earnings beat for Himax this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.
Himax has an Earnings ESP of 0.00% and a Zacks Rank #2. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks to Consider
Here are some companies worth considering from the sector as our model shows that these have the right combination of elements to beat on earnings this reporting cycle
CDW Corporation (CDW - Free Report) has an Earnings ESP of +0.51% and carries a Zacks Rank of 2, at present.
Synaptics Incorporated (SYNA - Free Report) has an Earnings ESP of +1.6% and currently carries a Zacks Rank of 2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Himax (HIMX) to Report Q1 Earnings: What's in the Cards?
Himax Technologies (HIMX - Free Report) is set to report first-quarter 2021 results on May 6.
The Zacks Consensus Estimate for revenues is currently pegged at $302.8 million, indicating growth of 64% from the year-ago quarter’s reported figure.
Moreover, the consensus mark for earnings has been stable at 38 cents per share in the past seven days. Meanwhile, Himax reported earnings of 2 cents per share in the year-ago quarter.
Let’s see how things are shaping up for this announcement.
Himax Technologies, Inc. Price and EPS Surprise
Himax Technologies, Inc. price-eps-surprise | Himax Technologies, Inc. Quote
Himax’s Solid Preliminary Results
Himax delivered impressive preliminary first-quarter 2021 results. Revenues of $309 million increased 12.1% sequentially and 67.4% year over year. The company’s earlier guidance suggested an increase between 5% and 10%, sequentially.
Earnings per ADS on non-IFRS basis are expected to be 38.4 cents, exceeding the prior guidance of 30.1-34.1 cents per ADS.
Further, the company’s gross margin exceeded its guidance, reflecting stringent cost-control efforts.
Factors to Consider
Himax is likely to have gained from a rebounding smartphone market, which is expected to have led to an uptick in demand for its smartphone TDDI solutions, AMOLED driver ICs and PMIC for 5G smartphones.
Continued momentum in demand for automotive driver ICs, owing to recovery in the automotive sector along with increasing usage of WLO in technologies across nanoimprinting manufacturing and diffraction optics might have acted as tailwinds.
Solid demand for high-end monitor and new-generation low-power notebooks and tablets owing to the coronavirus-led continuation in work-from-home and online-learning set up is expected to have triggered the need for Himax’s display driver ICs and timing controllers, which in turn, might have impacted first-quarter top line.
Momentum for its CMOS image sensors across IP camera and notebook is expected to have contributed to first-quarter revenues.
However, weakness in TDIC sales as well as traditional smartphone DDICs is likely to have acted as headwinds. Also, the company had earlier noted (Feb 4, 2021) that it expects AMOLED IC sales to witness sequential decline in the first quarter due to capacity shortage.
What Our Model Says
Our proven model doesn’t conclusively predict an earnings beat for Himax this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.
Himax has an Earnings ESP of 0.00% and a Zacks Rank #2. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks to Consider
Here are some companies worth considering from the sector as our model shows that these have the right combination of elements to beat on earnings this reporting cycle
Vishay Intertechnology (VSH - Free Report) has an Earnings ESP of +5.22% and sports a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
CDW Corporation (CDW - Free Report) has an Earnings ESP of +0.51% and carries a Zacks Rank of 2, at present.
Synaptics Incorporated (SYNA - Free Report) has an Earnings ESP of +1.6% and currently carries a Zacks Rank of 2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>